The Lead Episode 73: A Discussion of Time to Benefit and Harm of Direct Oral Anticoagulants in Device-Detected Atrial Fibrillation-The Lead Episode 73 Speaker Information

The Lead Episode 73 Speaker Information

Pdf Summary

This document discusses the analysis of two trials, NOAH-AFNET 6 and ARTESiA, focusing on the time required for direct oral anticoagulants to show benefits and harms in device-detected atrial fibrillation. The article was published in the Journal of the American College of Cardiology: Clinical Electrophysiology. The document was hosted by William H. Sauer, MD, FHRS, CCDS from Brigham and Women's Hospital, with contributions from Graham Peigh, MD, MS from Northwestern Memorial Hospital and Rod S. Passman, MD, FHRS from Northwestern University. Disclosures included information about honoraria, speaking engagements, consulting work, and research funding received by Rod S. Passman and William H. Sauer from various pharmaceutical and medical device companies. Graham Peigh had no disclosures to make. The study examined the effectiveness and potential risks associated with direct oral anticoagulants for atrial fibrillation patients monitored through devices.

Keywords

NOAH-AFNET 6

ARTESiA

direct oral anticoagulants

device-detected atrial fibrillation

Journal of the American College of Cardiology: Clinical Electrophysiology

William H. Sauer

Graham Peigh

Rod S. Passman

Brigham and Women's Hospital

Northwestern Memorial Hospital